Bupropion HCl, a new nontricyclic antidepressant, produced marked
improvement in 49 hospitalized patients with primary depression at doses of
300-600 mg/day. Bupropion resulted in statistically significant differences
from placebo as early as day 5, and by the end of the 4-week study 79% (N =
27) of the bupropion patients and 13% (N = 2) of the placebo patients
showed much to very much improvement. Bupropion and placebo had similar
side effect profiles. Tremor and sweating were reported more often with
bupropion and headache, nausea, and tiredness with placebo.